AACR 2024 | Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma

Marina Baretti, MD, Johns Hopkins University School of Medicine, Baltimore, MD, presents the results from the Phase I trial (NCT03299946) of a peptide vaccine with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma (FLC). The vaccine targets the DNAJB1-PRKACA fusion protein expressed only in cancerous cells. In combination with immune checkpoint inhibitors (ICIs), the trial saw durable responses. Blood analyses are being undertaken to establish the mechanism of response to the vaccine. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.